ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Mainz BioMed NV

Mainz BioMed NV (MYNZ)

0,340885
0,05089
( 17,55% )
Aktualisiert: 17:32:12

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Wichtige Statistiken und Details

Current Price
0,340885
Gebot
0,34
Fragen
0,3459
Volumen
2.006.957
0,285 Tagesbereich 0,3681
0,1852 52-Wochen-Bereich 3,3923
Marktkapitalisierung
Handelsende
0,29
Handelsbeginn
0,298
Letzte Trade
100
@
0.340885
Letzter Handelszeitpunkt
17:32:12
Finanzvolumen
US$ 645.088
VWAP
0,321426
Durchschnittliches Volumen (3 Mio.)
1.725.770
Ausgegebene Aktien
21.165.482
Dividendenrendite
-
Kurs-Gewinn-Verhältnis
0,00
Gewinn pro Aktie (EPS)
-
Erlöse
895k
Nettogewinn
-26,3M

Über Mainz BioMed NV

Mainz Biomed BV is engaged in developing molecular genetic diagnostic solutions for life-threatening conditions. It's main product Coloalert is a kit that includes a stool collector and shipping instructions to return the kit through regular mail to their local lab for testing and results. Mainz Biomed BV is engaged in developing molecular genetic diagnostic solutions for life-threatening conditions. It's main product Coloalert is a kit that includes a stool collector and shipping instructions to return the kit through regular mail to their local lab for testing and results.

Sektor
Testing Laboratories
Branche
Testing Laboratories
Hauptsitz
Amsterdam, North Holland, Nld
Gegründet
-
Mainz BioMed NV is listed in the Testing Laboratories sector of the NASDAQ with ticker MYNZ. The last closing price for Mainz BioMed NV was US$0,29. Over the last year, Mainz BioMed NV shares have traded in a share price range of US$ 0,1852 to US$ 3,3923.

Mainz BioMed NV currently has 21.165.482 shares in issue. The market capitalisation of Mainz BioMed NV is US$6,14 million.

MYNZ Neueste Nachrichten

Mainz Biomed Reports Increased Demand for Enhanced ColoAlert, Existing Partners to Transition to New Version

BERKELEY, Calif. and MAINZ, Germany, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in...

Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025

BERKELEY, Calif. and MAINZ, Germany, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in...

Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand Ambassador

BERKELEY, Calif. and MAINZ, Germany, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in...

Mainz Biomed Partners with Liquid Biosciences to Leverage the Power of Artificial Intelligence for the Expansion and Optimization of Biomarker Selection for PancAlert

BERKELEY, Calif. and MAINZ, Germany, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in...

Mainz Biomed Launches Enhanced ColoAlert with Cutting-Edge Features to Optimize Screening Efficiency and User Convenience

BERKELEY, Calif. and MAINZ, Germany, July 25, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular genetics diagnostic company specializing in early detection of cancer, today...

Mainz Biomed Announces Submission for FDA Breakthrough Device Designation for its Next Generation CRC Screening Test

On the basis of its positive clinical studies Mainz Biomed has now defined the final configuration including its novel mRNA biomarkers of the Next Generation Test to be used in pivotal...

Mainz Biomed Provides Half Year 2024 Corporate Update

BERKELEY, Calif. and MAINZ, Germany, July 02, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular genetics diagnostic company specializing in the early detection of cancer...

Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024

New study data confirmed previous ColoFuture and eAArly DETECT study performance with sensitivity for CRC of 92% and 82% for advanced adenomas, including 95.8% detection of high-grade dysplasia...

Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
10.07088526.25370370370.270.36810.2320754650.26369049CS
40.0018850.556047197640.3390.36810.185222047560.25950568CS
12-0.075715-18.17450792130.41660.47510.185217257700.3209668CS
26-0.749115-68.7261467891.091.130.185210970810.37891667CS
52-2.529115-88.12247386762.873.39230.18526312100.49145013CS
156-14.009115-97.624494773514.35300.18523028443.96759593CS
260-14.009115-97.624494773514.35300.18523028443.96759593CS
  • Volumen
  • % Tops
  • % Flops
SymbolPreisVol.
MNTSMomentus Inc
US$ 0,8427
(103,06%)
248,98M
BNZIBanzai International Inc
US$ 4,645
(68,30%)
30,15M
KXINKaixin Holdings
US$ 0,251
(39,44%)
118,93M
HOLOMicroCloud Hologram Inc
US$ 7,12
(37,50%)
24,07M
WWWW International Inc
US$ 1,595
(37,50%)
99,47M
SPGCSacks Parente Golf Inc
US$ 1,94
(-45,35%)
343,17k
BYUBAIYU Holdings Inc
US$ 0,6275
(-37,87%)
3,19M
ALCEAlternus Clean Energy Inc
US$ 0,098
(-31,99%)
8,88M
NISNNiSun International Enterprise Development Group Company Ltd
US$ 14,20
(-25,96%)
819,13k
VERBVerb Technology Company Inc
US$ 6,5254
(-23,23%)
212,98k
MNTSMomentus Inc
US$ 0,8427
(103,06%)
248,98M
NVDANVIDIA Corporation
US$ 133,0501
(0,12%)
122,18M
KXINKaixin Holdings
US$ 0,251
(39,44%)
118,93M
WWWW International Inc
US$ 1,595
(37,50%)
99,47M
SQQQProShares UltraPro Short QQQ
US$ 7,24
(-1,36%)
53,62M
Keine Diskussionen Gefunden.
Neuen Thread Erstellen

Kürzlich von Ihnen besucht

Delayed Upgrade Clock